This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation The aim of this trial is to explore the real-world effectiveness T-Dxd and potential predictors in Russian metastatic breast cancer patients
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. Intravenous infusion
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation
Moscow, Russia
RECRUITINGPFS
progression-free survival
Time frame: 6 weeks
ORR
Overall Response Rate
Time frame: 6 weeks
CBR
Clinical benefit Rates
Time frame: 6 weeks
OS
Overall Survival
Time frame: 6 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Safety
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.